化学療法薬誘発性肢端紅斑(手足症候群)治療の世界市場規模・現状・予測2021年-2027年

QYResearchが発行した調査報告書(QY21APR1271)
◆英語タイトル:Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size, Status and Forecast 2021-2027
◆商品コード:QY21APR1271
◆発行会社(リサーチ会社):QYResearch
◆発行日:2021年4月
◆ページ数:94
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥526,500見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥789,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査資料では、化学療法薬誘発性肢端紅斑(手足症候群)治療の世界市場(2016年~2027年)を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模(鎮痛剤、抗炎症剤・抗浮腫剤、抗ヒスタミン剤、NSAID、経口/局所グルココルチコイド、ピリドキシン(ビタミンB6)、その他)、用途別市場規模(薬局・ドラッグストア、病院薬局、オンラインドラッグストア)、主要地域別市場規模(北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等)、企業情報などをまとめております。
・市場概要
・化学療法薬誘発性肢端紅斑(手足症候群)治療の市場動向
・企業の競争状況、市場シェア
・化学療法薬誘発性肢端紅斑(手足症候群)治療の種類別市場規模(鎮痛剤、抗炎症剤・抗浮腫剤、抗ヒスタミン剤、NSAID、経口/局所グルココルチコイド、ピリドキシン(ビタミンB6)、その他)
・化学療法薬誘発性肢端紅斑(手足症候群)治療の用途別市場規模(薬局・ドラッグストア、病院薬局、オンラインドラッグストア)
・化学療法薬誘発性肢端紅斑(手足症候群)治療の北米市場規模2016-2027(アメリカ、カナダ)
・化学療法薬誘発性肢端紅斑(手足症候群)治療の欧州市場規模2016-2027(ドイツ、フランス、イギリス等)
・化学療法薬誘発性肢端紅斑(手足症候群)治療のアジア市場規模2016-2027(日本、中国、韓国、インド、東南アジア等)
・化学療法薬誘発性肢端紅斑(手足症候群)治療の中南米市場規模2016-2027(メキシコ、ブラジル)
・化学療法薬誘発性肢端紅斑(手足症候群)治療の中東・アフリカ市場規模2016-2027(トルコ、サウジアラビア等)
・主要企業情報(Taro、Oceanside Pharmaceuticals、Pfizer、Novartis、A-S Medication Solutions、Preferred Pharmaceuticals、Syntex Pharmaceuticals、Valeant Canada、Technilab Pharma、Allergan)
・結論
【レポートの概要】

Acral erythema, also called as hand-foot syndrome or palmar-plantar erythrodysesthesia, is characterized by swelling, redness, paraesthesia (numbness) and desquamation (skin peeling) of palms, soles and rarely on knees and elbow. Acryl erythema is an adverse drug reaction which typically appear after several months of treatment with chemotherapeutic agents, gemcitabine and fluorouracil being the most common drugs causing reaction. Chemotherapy induced acryl erythema is a dose dependent condition, regression of which can be achieved by discontinuation of chemotherapy or by dose reduction. Treatment for chemotherapy induced acryl erythema includes symptomatic treatment with analgesics and antihistaminic drugs to reduce pain and edema.
Surge in usage of chemotherapeutic agents due to increasing incidence of cancers is the major growth driver of global chemotherapy induced acral erythema treatment market.Moreover, lifestyle up-gradation, increasing number of smokers are some secondary considerations accountable for rise in global chemotherapy induced acral erythema treatment market.

Market Analysis and Insights: Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market
The global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment market.

Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Scope and Market Size
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Analgesics
Anti-Inflammatory And Anti-Edematous Agents
Antihistaminic
NSAIDs
Oral/Topical Glucocorticoids
Pyridoxine (Vitamin B6)
Others

Segment by Application
Pharmacy And Drugstores
Hospital Pharmacy
Online Drug Stores

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Taro
Oceanside Pharmaceuticals
Pfizer
Novartis
A-S Medication Solutions
Preferred Pharmaceuticals
Syntex Pharmaceuticals
Valeant Canada
Technilab Pharma

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Analgesics
1.2.3 Anti-Inflammatory And Anti-Edematous Agents
1.2.4 Antihistaminic
1.2.5 NSAIDs
1.2.6 Oral/Topical Glucocorticoids
1.2.7 Pyridoxine (Vitamin B6)
1.2.8 Others
1.3 Market by Application
1.3.1 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Pharmacy And Drugstores
1.3.3 Hospital Pharmacy
1.3.4 Online Drug Stores
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Perspective (2016-2027)
2.2 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Growth Trends by Regions
2.2.1 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Industry Dynamic
2.3.1 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Trends
2.3.2 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Drivers
2.3.3 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Challenges
2.3.4 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Players by Revenue
3.1.1 Global Top Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Players by Revenue (2016-2021)
3.1.2 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue
3.4 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Concentration Ratio
3.4.1 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue in 2020
3.5 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Key Players Head office and Area Served
3.6 Key Players Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Product Solution and Service
3.7 Date of Enter into Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Breakdown Data by Type
4.1 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Historic Market Size by Type (2016-2021)
4.2 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Forecasted Market Size by Type (2022-2027)

5 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Breakdown Data by Application
5.1 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Historic Market Size by Application (2016-2021)
5.2 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size (2016-2027)
6.2 North America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type
6.2.1 North America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type (2016-2021)
6.2.2 North America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type (2022-2027)
6.2.3 North America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type (2016-2027)
6.3 North America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application
6.3.1 North America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application (2016-2021)
6.3.2 North America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application (2022-2027)
6.3.3 North America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application (2016-2027)
6.4 North America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Country
6.4.1 North America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Country (2016-2021)
6.4.2 North America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size (2016-2027)
7.2 Europe Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type
7.2.1 Europe Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type (2016-2021)
7.2.2 Europe Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type (2022-2027)
7.2.3 Europe Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type (2016-2027)
7.3 Europe Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application
7.3.1 Europe Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application (2016-2021)
7.3.2 Europe Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application (2022-2027)
7.3.3 Europe Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application (2016-2027)
7.4 Europe Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Country
7.4.1 Europe Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Country (2016-2021)
7.4.2 Europe Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size (2016-2027)
8.2 Asia-Pacific Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type
8.2.1 Asia-Pacific Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application
8.3.1 Asia-Pacific Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Region
8.4.1 Asia-Pacific Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size (2016-2027)
9.2 Latin America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type
9.2.1 Latin America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type (2016-2027)
9.3 Latin America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application
9.3.1 Latin America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application (2016-2027)
9.4 Latin America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Country
9.4.1 Latin America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size (2016-2027)
10.2 Middle East & Africa Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type
10.2.1 Middle East & Africa Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application
10.3.1 Middle East & Africa Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Country
10.4.1 Middle East & Africa Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Taro
11.1.1 Taro Company Details
11.1.2 Taro Business Overview
11.1.3 Taro Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Introduction
11.1.4 Taro Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Business (2016-2021)
11.1.5 Taro Recent Development
11.2 Oceanside Pharmaceuticals
11.2.1 Oceanside Pharmaceuticals Company Details
11.2.2 Oceanside Pharmaceuticals Business Overview
11.2.3 Oceanside Pharmaceuticals Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Introduction
11.2.4 Oceanside Pharmaceuticals Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Business (2016-2021)
11.2.5 Oceanside Pharmaceuticals Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Introduction
11.3.4 Pfizer Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Business (2016-2021)
11.3.5 Pfizer Recent Development
11.4 Novartis
11.4.1 Novartis Company Details
11.4.2 Novartis Business Overview
11.4.3 Novartis Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Introduction
11.4.4 Novartis Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Business (2016-2021)
11.4.5 Novartis Recent Development
11.5 A-S Medication Solutions
11.5.1 A-S Medication Solutions Company Details
11.5.2 A-S Medication Solutions Business Overview
11.5.3 A-S Medication Solutions Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Introduction
11.5.4 A-S Medication Solutions Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Business (2016-2021)
11.5.5 A-S Medication Solutions Recent Development
11.6 Preferred Pharmaceuticals
11.6.1 Preferred Pharmaceuticals Company Details
11.6.2 Preferred Pharmaceuticals Business Overview
11.6.3 Preferred Pharmaceuticals Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Introduction
11.6.4 Preferred Pharmaceuticals Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Business (2016-2021)
11.6.5 Preferred Pharmaceuticals Recent Development
11.7 Syntex Pharmaceuticals
11.7.1 Syntex Pharmaceuticals Company Details
11.7.2 Syntex Pharmaceuticals Business Overview
11.7.3 Syntex Pharmaceuticals Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Introduction
11.7.4 Syntex Pharmaceuticals Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Business (2016-2021)
11.7.5 Syntex Pharmaceuticals Recent Development
11.8 Valeant Canada
11.8.1 Valeant Canada Company Details
11.8.2 Valeant Canada Business Overview
11.8.3 Valeant Canada Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Introduction
11.8.4 Valeant Canada Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Business (2016-2021)
11.8.5 Valeant Canada Recent Development
11.9 Technilab Pharma
11.9.1 Technilab Pharma Company Details
11.9.2 Technilab Pharma Business Overview
11.9.3 Technilab Pharma Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Introduction
11.9.4 Technilab Pharma Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Business (2016-2021)
11.9.5 Technilab Pharma Recent Development
11.10 Allergan
11.10.1 Allergan Company Details
11.10.2 Allergan Business Overview
11.10.3 Allergan Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Introduction
11.10.4 Allergan Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Business (2016-2021)
11.10.5 Allergan Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details



【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 化学療法薬誘発性肢端紅斑(手足症候群)治療の世界市場規模・現状・予測2021年-2027年(Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size, Status and Forecast 2021-2027)]についてメールでお問い合わせはこちらでお願いします。